YHYoshiyuki Hattori

Yoshiyuki Hattori

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoshiyuki Hattori has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • Kikuo Kasai

    From the *Department of Endocrinology and Metabolism, Dokkyo University School of Medicine, Mibu, Tochigi, Japan; †Department of Biochemistry, Meikai University School of Medicine, Sakado, Saitama, Japan; and ‡Department of Biochemistry, Dokkyo University School of Medicine, Mibu, Tochigi, Japan

    23 shared publications
  • Kazumi Akimoto

    Department of Endocrinology and Metabolism , Dokkyo University School of Medicine , Mibu, Tochigi 321-0293 , Japan

    9 shared publications
  • Nobuo Nakanishi

    From the *Department of Endocrinology and Metabolism, Dokkyo University School of Medicine, Mibu, Tochigi, Japan; †Department of Biochemistry, Meikai University School of Medicine, Sakado, Saitama, Japan; and ‡Department of Biochemistry, Dokkyo University School of Medicine, Mibu, Tochigi, Japan

    9 shared publications
  • K. Kasai

    Department of Endocrinology and Metabolism, Dokkyo University School of Medicine, Mibu, Japan

    8 shared publications
  • Sachiko Hattori

    Department of Endocrinology and Metabolism , Dokkyo University School of Medicine , Mibu, Tochigi 321-0293 , Japan

    8 shared publications
  • Kunihiro Suzuki

    Department of Endocrinology and Metabolism, Dokkyo University School of Medicine, Mibu, Japan

    7 shared publications

Latest Publications

  • Differential Modulation of Immunostimulant-Triggered NO Production by Endoplasmic Reticulum Stress Inducers in Vascular Smooth Muscle Cells

    by Satoshi Ohta, Yoshiyuki Hattori, Nobuo Nakanishi, Hiroyuki Sugimoto, Kikuo Kasai

    We investigated the effects of endoplasmic reticulum (ER) stress inducers thapsigargin (TG) and tunicamycin (Tm) on immunostimulant lipopolysaccharide/interferon (LPS/IFN)-induced expression of isoform of nitric oxide synthase (iNOS) and nitric oxide (NO) production in vascular smooth muscle cells. LPS/IFN-induced iNOS mRNA expression was markedly enhanced by TG, whereas iNOS mRNA expression was strongly attenuated by Tm. Similarly, production of iNOS protein was markedly upregulated by TG but virtually eliminated by Tm. LPS/IFN-induced guanosine triphosphate cyclohydrolase I mRNA expression was slightly reduced by TG and markedly inhibited by Tm. Similarly, LPS/IFN-mediated induction of cellular biopterin was modestly reduced by TG and markedly inhibited by Tm. TG modestly enhanced LPS/IFN-induced activation of NF-κB, whereas Tm had no effect on it. Cellular respiration was reduced by TG and Tm in a concentration-dependent manner, which was confirmed by apoptosis assay. Thus, TG and Tm-induced ER stress and differently modulated NO production through alterations in iNOS expression and activity independently of NF-κB activation and caused a similar degree of ER stress-induced apoptosis.


  • Open Access

    Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients

    by Yoshiaki Kawagoe, Yoshiyuki Hattori, Ayuko Nakano, Chie Aoki, Seiichi Tanaka, Satoshi Ohta, Toshie Iijima, Atsuko Tomizawa, Teruo Jojima, Hiroyuki Kase, et al.

    It is well established that statins improve the prognosis of patients with coronary artery disease. However, it is still unclear whether the protective effects of statins relate to lipid lowering alone or whether other pleiotropic effects may contribute. Thus, we compared the endothelial function among two groups of diabetic patients treated with fluvastatin 60 mg (F60) or fluvastatin 20 mg combined with ezetimibe 10 mg (F20/E10). The endothelial function was evaluated by measuring flow-mediated vasodilatation (FMD) at baseline and follow-up at 10 weeks. Similar improvements in FMD were observed in the two groups. The reduction in low-density lipoprotein cholesterol (LDL-C) was less pronounced in the F60 group, compared with the F20/E10 group. A significant reduction in remnant-like lipoprotein particles cholesterol (RLP-C) was observed in the F20/E10 group, but not in the F60 group. A correlation between the observed reduction in LDL-C or RLP-C and the improvement in FMD was observed in F20/E10 group. These results suggest that high-dose fluvastatin might have pleiotropic effects of potential clinical benefit, and that the combination of ezetimibe with a reduced dose of fluvastatin may also significantly improve endothelial function with reduction of LDL-C and RLP-C.


    • 1 November 2010
      • p. 186-9

    [Phosphodiesterase-3 inhibitor].

    by Yoshiaki Kawagoe, Yoshiyuki Hattori, Kikuo Kasai

  • Effects of statins on vascular endothelial function in hypercholesterolemic patients with type 2 diabetes mellitus: Fluvastatin vs. rosuvastatin

    by Atsuko Tomizawa, Yoshiyuki Hattori, Kunihiro Suzuki, Toshie Okayasu, Hiroyuki Kase, Hiroko Satoh, Kikuo Kasai


  • Retracted

    RETRACTED ARTICLE: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells

    by Y. Hattori, T. Jojima, A. Tomizawa, H. Satoh, S. Hattori, K. Kasai, T. Hayashi

    Glucagon-like peptide-1 (GLP-1), a member of the proglucagon-derived peptide family, was seen to exert favourable actions on cardiovascular function in preclinical and clinical studies. The mechanisms through which GLP-1 modulates cardiovascular function are complex and incompletely understood. We thus investigated whether the GLP-1 analogue, liraglutide, which is an acylated GLP-1, has protective effects on vascular endothelial cells. Nitrite and nitrate were measured in medium with an automated nitric oxide detector. Endothelial nitric oxide synthase (eNOS) activation was assessed by evaluating the phosphorylation status of the enzyme and evaluating eNOS activity by citrulline synthesis. Nuclear factor κB (NF-κB) activation was assessed by reporter gene assay. Liraglutide dose-dependently increased nitric oxide production in HUVECs. It also caused eNOS phosphorylation, potentiated eNOS activity and restored the cytokine-induced downregulation of eNOS (also known as NOS3) mRNA levels, which is dependent on NF-κB activation. We therefore examined the effect of liraglutide on TNFα-induced NF-κB activation and NF-κB-dependent expression of proinflammatory genes. Liraglutide dose-dependently inhibited NF-κB activation and TNFα-induced IκB degradation. It also reduced TNFα-induced MCP-1 (also known as CCL2), VCAM1, ICAM1 and E-selectin mRNA expression. Liraglutide-induced enhancement of nitric oxide production and suppression of NF-κB activation were attenuated by the AMP-activated protein kinase (AMPK) inhibitor compound C or AMPK (also known as PRKAA1) small interfering RNA. Indeed, liraglutide induced phosphorylation of AMPK, which occurs through a signalling pathway independent of cyclic AMP. Liraglutide exerts an anti-inflammatory effect on vascular endothelial cells by increasing nitric oxide production and suppressing NF-κB activation, partly at least through AMPK activation. These effects may explain some of the observed vasoprotective properties of liraglutide, as well as its beneficial effects on the cardiovascular system.


  • Glimepiride upregulates eNOS activity and inhibits cytokine‐induced NF‐κB activation through a phosphoinoside 3‐kinase–Akt‐dependent pathway

    by T. Jojima, K. Suzuki, N. Hirama, K. Uchida, Y. Hattori

    Aims:  Several studies suggest increased mortality postcoronary angioplasty in patients on sulphonylureas. However, a theoretical reduction in cardiac risk has been suggested with the newer sulphonylurea agents, which differ from the first‐generation agents. In the present study, we investigated whether a third generation of sulphonylurea, glimepiride, might stimulate nitric oxide (NO) production and thereby inhibit cytokine‐induced nuclear factor (NF)‐κB activation in endothelial cells compared with the classical sulphonylurea glibenclamide. Methods and Results:  We demonstrated that glimepiride, but not glibenclamide, induces NO production in human umbilical vein endothelial cells (HUVEC). A significant increase in endothelial NO synthase (eNOS) activity, measured in terms of citrulline production, was observed with glimepiride treatment. Akt phosphorylation followed by phosphorylation of eNOS (Ser1177) was observed with glimepiride treatment in HUVEC. Moreover, two phosphoinoside 3‐kinase inhibitors, wortmannin and LY294002, significantly inhibited glimepiride‐induced NO production. We also demonstrated inhibition of tumour necrosis factor‐alpha (TNFα)‐induced NF‐κB activation in HUVEC treated with glimepiride, which was attenuated by pretreatment with N ω ‐nitro‐ l ‐arginine methyl ester. We also demonstrated a marked increase in p65 in nuclear extracts from untreated HUVEC following stimulation with TNFα, which was dose dependently inhibited by glimepiride, but not by glibenclimide in association with NF‐κB levels. Conclusion:  These data suggest that glimepiride might be a preferable sulphonylurea agent in the setting of type 2 diabetes and vascular disease because it may have protective effects on vascular endothelial cells.


  • Retracted
    Open Access

    Cilostazol inhibits cytokine-induced nuclear factor- B activation via AMP-activated protein kinase activation in vascular endothelial cells

    by Yoshiyuki Hattori, Kunihiro Suzuki, Atsuko Tomizawa, Noriko Hirama, Toshie Okayasu, Sachiko Hattori, Hiroko Satoh, Kazumi Akimoto, Kikuo Kasai

    Cilostazol is a selective inhibitor of phosphodiesterase 3 that increases intracellular cyclic AMP (cAMP) levels and activates protein kinase A, thereby inhibiting platelet aggregation and inducing peripheral vasodilation. We hypothesized that cilostazol may prevent inflammatory cytokine induced-nuclear factor (NF)-κB activation by activating AMP-activated protein kinase (AMPK) in vascular endothelial cells. Cilostazol was observed to activate AMPK and its downstream target, acetyl-CoA carboxylase, in human umbilical vein endothelial cells (HUVEC). Phosphorylation of AMPK with cilostazol was not affected by co-treatment with an adenylate cyclase inhibitor, SQ 22536, and a cell-permeable cAMP analogue, pCTP-cAMP, did not induce AMPK phosphorylation and had no effect on cilostazol-induced AMPK phosphorylation, suggesting that cilostazol-induced AMPK activation occurs through a signalling pathway independent of cyclic AMP. Cilostazol also dose-dependently inhibited tumour necrosis factor alpha (TNFα)-induced NF-κB activation and TNFα-induced IκB kinase activity. Furthermore, cilostazol attenuated the TNFα-induced gene expression of various pro-inflammatory and cell adhesion molecules, such as vascular cell adhesion molecule-1, E-selectin, intercellular adhesion molecule-1, monocyte chemoattractant protein-1 (MCP-1), and PECAM-1 in HUVEC. RNA interference of AMPKα1 or the AMPK inhibitor compound C attenuated cilostazol-induced inhibition of NF-κB activation by TNFα. In the light of these findings, we suggest that cilostazol might attenuate the cytokine-induced expression of adhesion molecule genes by inhibiting NF-κB following AMPK activation.


  • Open Access

    Cilostazol Activates AMP-activated Protein Kinase and Restores Endothelial Function in Diabetes

    by Kunihiro Suzuki, Kohsuke Uchida, Nobuo Nakanishi, Yoshiyuki Hattori

    Background. Endothelial dysfunction plays a key role in atherogenesis. We investigated whether AMP-activated protein kinase (AMPK) activity is a downst